Spectrum completes Zevalin buyout from Cell Therapeutics
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals has completed its acquisition of RIT Oncology from Cell Therapeutics (CTI), a move which hands it the US rights to Zevalin (ibritumomab tiuxetan). The $16.5 million deal ends the joint venture the companies set up at the end of 2008 with Spectrum now booking all of Zevalin's revenues.